Is CDUFA Next? Hamburg Wants Congress To Think About A Compounder User Fee
This article was originally published in The Pink Sheet Daily
FDA commissioner says in a blog post that the additional authority FDA requires to oversee compounders also would require more money, which could come through registration or other fees.
You may also be interested in...
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
NMEs and novel biologics will see reviews allotted two additional months under the revised model launching Oct. 1. Industry expects to gain more communication and first-cycle approvals, while FDA hopes it can receive more complete applications at submission and improve transparency.
Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.